[New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus ® tablets), an oral GLP-1 receptor agonist].
Level 5 - mechanism / opinion, no new human data
Narrative review and drug introduction with no primary data or systematic synthesis
PubMed 35228448 · doi:10.1254/fpj.21052
What was done
This paper provides an overview of the pharmacology, molecular structure, and clinical development of oral semaglutide (Rybelsus) for type 2 diabetes. It describes the co-formulation of semaglutide with the absorption promoter sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC) and references evidence from eight global clinical trials and two Japanese trials assessing 3, 7, and 14 mg daily doses as monotherapy or combination therapy.
What was found
The abstract reports no numerical outcome data, effect sizes, or statistical values. It notes that semaglutide exhibits 94% amino acid homology with human GLP-1 and that oral semaglutide at doses of 3, 7, and 14 mg provided continuous benefit across eight global and two Japanese clinical trials in type 2 diabetes.
Why it matters
Oral semaglutide provides the first non-injectable GLP-1 receptor agonist option, potentially facilitating earlier initiation and adherence in the management of progressive type 2 diabetes.
Limits
The abstract contains no quantitative findings, confidence intervals, sample sizes, or safety data. As a narrative review and drug introduction, it lacks a systematic literature search, standardized trial appraisal, and primary comparative data.
Cited by
- supports Semaglutide shares 93% or 94% sequence homology with native human GLP-1.